ESMO Asia 2015 Press Release: More Patients with Lung Cancer Could Benefit from Immunotherapy, Study Shows
KEYNOTE-010 data further supports broadening pembrolizumab availability for all advanced NSCLC patients with PD-L1 expression over 1% SINGAPORE/LUGANO – More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from…